An early study to arm T cells with tumour‐specific chemokine receptors was done to target Hodgkin tumour cells, for which T cells were engineered to produce high thymus‐ and activation‐regulated chemokine/CC chemokine ligand 17 (TARC/CCL17) and macrophage‐derived chemokine.15 This evidence concerns the gene CCL17 and neoplasm.